TW200718421A - Use of an epidermal growth factor receptor kinase inhibitor (EGFR) in gefitinib resistant patients - Google Patents

Use of an epidermal growth factor receptor kinase inhibitor (EGFR) in gefitinib resistant patients

Info

Publication number
TW200718421A
TW200718421A TW095112747A TW95112747A TW200718421A TW 200718421 A TW200718421 A TW 200718421A TW 095112747 A TW095112747 A TW 095112747A TW 95112747 A TW95112747 A TW 95112747A TW 200718421 A TW200718421 A TW 200718421A
Authority
TW
Taiwan
Prior art keywords
kinase inhibitor
egfr
growth factor
factor receptor
epidermal growth
Prior art date
Application number
TW095112747A
Other languages
English (en)
Inventor
Charles M Zacharchuk
Susan E Quinn
Patricia Martins
Lee Greenberger
Ante Bill Lundberg
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of TW200718421A publication Critical patent/TW200718421A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW095112747A 2005-04-14 2006-04-10 Use of an epidermal growth factor receptor kinase inhibitor (EGFR) in gefitinib resistant patients TW200718421A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US67128705P 2005-04-14 2005-04-14

Publications (1)

Publication Number Publication Date
TW200718421A true TW200718421A (en) 2007-05-16

Family

ID=36791648

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095112747A TW200718421A (en) 2005-04-14 2006-04-10 Use of an epidermal growth factor receptor kinase inhibitor (EGFR) in gefitinib resistant patients

Country Status (19)

Country Link
US (1) US20060235046A1 (zh)
EP (1) EP1871371A2 (zh)
JP (1) JP2008536847A (zh)
KR (1) KR20080002826A (zh)
CN (1) CN101160129A (zh)
AR (1) AR053357A1 (zh)
AU (1) AU2006236940A1 (zh)
BR (1) BRPI0610574A2 (zh)
CA (1) CA2646257A1 (zh)
CR (1) CR9415A (zh)
GT (1) GT200600146A (zh)
IL (1) IL186302A0 (zh)
MX (1) MX2007012662A (zh)
NO (1) NO20074722L (zh)
PE (1) PE20061396A1 (zh)
RU (1) RU2007134908A (zh)
TW (1) TW200718421A (zh)
WO (1) WO2006113151A2 (zh)
ZA (1) ZA200708755B (zh)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2364495T3 (es) * 2005-02-03 2011-09-05 The General Hospital Corporation Método para tratar cáncer resistente a gefitinib.
JP2009514870A (ja) 2005-11-04 2009-04-09 ワイス ｍＴＯＲインヒビター、ハーセプチン、および／またはＨＫＩ−２７２の抗悪性腫瘍性組み合わせ
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
ES2692769T3 (es) 2008-06-17 2018-12-05 Wyeth Llc Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina
CN105147713A (zh) * 2008-08-04 2015-12-16 惠氏有限责任公司 4-苯胺基-3-氰基喹啉和卡培他滨的抗肿瘤组合
JP2012501654A (ja) * 2008-09-05 2012-01-26 アビラ セラピューティクス， インコーポレイテッド 不可逆的インヒビターの設計のためのアルゴリズム
WO2010086382A1 (en) * 2009-01-30 2010-08-05 Pronota N.V. Target for treatment of acute heart failure
SG174382A1 (en) 2009-04-06 2011-11-28 Wyeth Llc Treatment regimen utilizing neratinib for breast cancer
NZ620174A (en) * 2009-09-16 2016-08-26 Celgene Avilomics Res Inc Protein kinase conjugates and inhibitors
EP2519664A4 (en) 2009-12-30 2014-03-12 Avila Therapeutics Inc LIGAND-RELATED COVALENTS MODIFYING A PROTEIN
KR102431436B1 (ko) 2014-08-29 2022-08-10 테스 파마 에스.알.엘. α-아미노-β-카복시뮤콘산 세미알데히드 데카복실라제의 억제제
US9364469B1 (en) * 2015-08-26 2016-06-14 Macau University Of Science And Technology Identification of a new AMPK activator for treatment of lung cancer
CA3112043A1 (en) 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
BRPI0413255A (pt) * 2003-08-01 2006-10-03 Wyeth Corp uso de uma combinação de um inibidor de quinase do receptor do fator de crescimento epidérmico e agentes citotóxicos para tratamento e inibição do cáncer
US7399865B2 (en) * 2003-09-15 2008-07-15 Wyeth Protein tyrosine kinase enzyme inhibitors
CN101501211A (zh) * 2004-03-31 2009-08-05 综合医院公司 测定癌症对表皮生长因子受体靶向性治疗反应性的方法
ES2364495T3 (es) * 2005-02-03 2011-09-05 The General Hospital Corporation Método para tratar cáncer resistente a gefitinib.

Also Published As

Publication number Publication date
AU2006236940A1 (en) 2006-10-26
JP2008536847A (ja) 2008-09-11
PE20061396A1 (es) 2007-01-12
BRPI0610574A2 (pt) 2010-07-06
US20060235046A1 (en) 2006-10-19
AR053357A1 (es) 2007-05-02
WO2006113151A2 (en) 2006-10-26
WO2006113151A3 (en) 2007-01-11
RU2007134908A (ru) 2009-05-20
MX2007012662A (es) 2008-04-04
EP1871371A2 (en) 2008-01-02
CN101160129A (zh) 2008-04-09
KR20080002826A (ko) 2008-01-04
CA2646257A1 (en) 2006-10-26
IL186302A0 (en) 2008-08-07
NO20074722L (no) 2007-11-12
CR9415A (es) 2008-01-21
ZA200708755B (en) 2008-10-29
GT200600146A (es) 2006-11-07

Similar Documents

Publication Publication Date Title
MXPA06001110A (es) Uso de una combinacion de un inhibidor de la cinasa del receptor del factor de crecimiento epidermico y agentes citotoxicos para el tratamiento e inhibicion del cancer.
NO20074722L (no) Anvendelse av en epidermal vekstfaktor reseptor kinase inhibitor (EGRR) i gefitinib resistente pasienter
AP1913A (en) Substituted benzazoles and use thereof as raf kinase inhibitors
MX2009009304A (es) Inhibidores de cinasa pim y metodos para su uso.
IS2855B (is) 4-anilínókínasólínafleiður sem andfjölgunarefni
IL174965A0 (en) SUBSTITUTED BENZAZOLES AND USE THEREOF AS INHIBITORS OF Raf KINASE
IL180137A0 (en) 2,4,6-trisubstituted pyrimidines as phosphotidylinositol (pi) 3-kinase inhibitors and their use in the treatment of cancer
CY1112478T1 (el) Ενωσεις κιναζολινονης ως αντικαρκινικοι παραγοντες
SI1742644T1 (sl) Terapevtski sestavek ki vsebuje vsaj en derivat pirolobenzodiazepina in fludarabin
IL184791A (en) Gaffitinib-Resistant Cancer Treatment Compounds A method to treat gafitinib-resistant cancer with an EGFR gene t790m using irreversible EGFR inhibitors
IL191832A (en) Pyridiazinone compounds and their use in the preparation of drugs for the treatment of tumors
TN2010000208A1 (en) Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents
IL194843A0 (en) Tetrahydropyrrolopyrimidinediones and their use as human neutrophil elastase inhibitors
NZ544719A (en) Combination of mGluR2 antagonist and aChE inhibitor for treatment of acute and/or chronic neurological disorders
MY154591A (en) Therapeutic compositions comprising a specific endothelin receptor antagonist and a pde5 inhibitor
MXPA05011858A (es) Agentes terapeuticos que comprenden un agente antiagiongenico en combinacion con un inhibidor src y su uso terapeutico.
EP1781296A4 (en) QUINAZOLINE DERIVATIVES, USE THEREOF IN THE TREATMENT OF THROMBOCYTHEMIA
MX2007000360A (es) Marcadores moleculares de pronostico.
GB0211230D0 (en) Treatment of heart failure
TNSN08512A1 (en) Treatment of tumors in pediatric patients with epidermal growth factor receptor antagonists
NZ610401A (en) Inhibitors of the mutant form of kit
AP2005003345A0 (en) 2, 4, 6-Trisubstituted pyrimidines as phosphotidylinositol (PI) 3-kinase inhibitors and their use inthe treatment of cancer
HK1103077A (zh) 作为磷脂酰肌醇(pi)3-激酶抑制剂的2，4，6-三取代的嘧啶及其在癌症治疗中的用途
HK1102590A (zh) 作为磷脂酰肌醇(pi)3-激酶抑制剂的2，4，6-三取代的嘧啶及其在癌症治疗中的用途
HK1099768A (zh) 作为磷脂酰肌醇(pi)3-激酶抑制剂的2，4，6-三取代的嘧啶及其在癌症治疗中的用途